Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BW 1014

Next Previous
Drug Profile

BW 1014

Alternative Names: BW-1014; H5N1 Influenza vaccine; Intranasal influenza virus vaccine - BlueWillow Biologics; NanoVax®-Panflu; NanoVax® W805EC; NanoVax® W805EC adjuvanted A/H5 vaccine; NE-01 - BlueWillow Biologics; NE-rH5 vaccine

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoBio Corporation
  • Developer BlueWillow Biologics
  • Class Adjuvants; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in USA (Intranasal)
  • 06 Nov 2025 Immunogenicity and adverse event data from a phase I trial in Influenza virus infections released by BlueWillow Biologics
  • 12 Oct 2023 BlueWillow Biologics completes the phase I IN-NE-rH5 trial for Influenza virus infections (Prevention) in USA (NCT05397119)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top